

Help

Bloomberg

Company In Depth Fundamentals - Profile

Ticker: [JNJ US EQUITY](#)

Johnson & Johnson (New York: JNJ, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos


Website	www.jnj.com
Number of Employees	144,300
Ticker:	JNJ US

1 Johnson & Johnson Plaza New Brunswick, NJ 08933 United States
Phone : 1-732-524-0400
Fax : --

173.91 -0.61 (-0.35%)

Johnson & Johnson fabrica productos de sanidad y provee servicios relacionados para los mercados de consumo, farmacéuticos, dispositivos médicos y de diagnósticos. Vende productos de piel y cabello, acetaminofénicos, farmacéuticos, equipo de diagnóstico y de cirugía alrededor del mundo.

Stock Quote & Chart (Currency: USD)			
Last (delayed quote)	173.91	Market Cap (MM)	457,240.7
Open	174.17	Shares Out. (MM)	2,629.2
Previous Close	174.52	Float %	99.9%
Change	0.32	Shares sold short (MM)	13,613,059.0
Change %	0.18	Dividend Yield %	2.5
Day High/Day Low	175.2 / 173.5	Diluted EPS Excl. XO	8.5
52 Wk High/52 Wk low	186.7 / 155.7	P / Diluted EPS Before XO	25.3
Volume (MM)	5.46	Beta	0.67
Avg. Vol - 3 mo (MM)	6.91		



Financial Information (Currency: USD, in mm)			
Revenue - LTM	95,588.0	Cash & ST Invst.	31,608
EBIT - LTM	22,731.0	Total Assets	182,018.0
EBITDA - LTM	29,901.0	Total Debt	34,751.0
Net Income - LTM	18,366.0	Total Liabilities	107,995.0
Total Enterprise Value	457,270	Total Equity	74,023.0
TEV/ Total Revenue	4.9 x	Cash from Operations - LTM	23,582.0
TEV/ EBITDA	15.8 x	Cash from Investing - LTM	-14,352.0
		Cash from Financing -LTM	-12,579.0


Company Notes	
2016 Q1	GAAP Net Income Includes: (in millions, pre-tax) A gain of \$402,000 from Litigation / Settlement
GAAP Net Income Include:(in millions, pre tax)	A loss of \$137 from Restructuring
A loss of \$137 from Restructuring	A loss of \$139,000 from Other One-Time Charges
A loss of \$66 from Litigation	A loss of \$32,000 from MERGER EXPENSE
	A gain of \$26,000 from Sale of Business
2015 A1	2014 A1
GAAP Net Income includes. (in millions, pre-tax):	GAAP Net Income Includes: (in millions, pre-tax)
a total loss of \$1,237,000	A gain of \$1,899,000 from sale of business
	A loss of \$1,253,000 from Legal Expense
2015 Q4	2014 Q4
GAAP Net Income includes. (in millions, pre-tax):	GAAP Net Income Includes: (in millions, pre-tax)
a loss of \$214,000 from Acquired In-Process R&D Expense	A gain of \$1948,000 from Sale of Business
a gain of \$33,000 from Sale of Business	A loss of \$346,000 from Other One Time Items
a loss of \$590,000 from Restructuring Charges	A loss of \$178,000 from acquired in R&D
a loss of \$83,000 from Other One-Time Charges	
	2014 Q3
2015 Q3	GAAP Net Income Includes: (in millions, pre-tax)
GAAP Net Income Includes: (in millions, pre-tax)	A loss of \$692,000 from Legal/Litigation
A loss of \$409,000 from Legal Expense	A loss of \$325,000 from Merger/Acquisition Expense
A loss of \$32,000 from Merger/Acquisition Expense	A loss of \$156,000 from Acquired In-Process RD
A loss of \$10,000 from Acquired In-Process RD	A loss of \$49,000 from Sale of Business
	2014 Q2
2015 Q2	GAAP Net Income Includes: (in millions, pre-tax)
GAAP Net Income Includes: (in millions, pre-tax)	A gain of \$1948,000 from Sale of Business
A loss of \$134,000 from Legal Expense	A loss of \$346,000 from Other One Time Items
A loss of \$49,000 from Merger/Acquisition Expense	A loss of \$285,000 from Legal Expense
A loss of \$9,000 from Other One Time Items	A loss of \$167,000 from Merger/Acquisition Expense
A gain of \$3,000 from Sale of Business	
2015 Q1	2014 Q2

Key Board Members			
Name	Title	Organization	
Anne M Mulcahy	Partner	Lead Edge Capital	
	Board Member	Williams-Sonoma Inc	
	Board Member	Graham Holdings Co	
	Board Member	Lpl Financial Holdings Inc	
Mark A Weinberger	Lead Director	Johnson & Johnson	
	Co-Founder	Washington Counsel Pc	
	Senior Advisor	Stone Canyon Industries Holdin	
	Board Member	Accelerate Acquisition Corp	
	Board Member	Saudi Arabian Oil Co	
	Board Member	Johnson & Johnson	
	Board Member	Metlife Inc	
Hubert Joly	Board Member	Bullis School	
	Board Member	Concord Coalition	
	Trustee	Case Western Reserve Universit	
	Trustee	United States Council For Inte	
	Board Member	National Bureau Of Economic Re	
	Lead Director	Ralph Lauren Corp	
Mark B Mcclellan	Board Member	Johnson & Johnson	
	Board Member	Minnesota Business Partnership	
	Founding Dir:Margolis Center For	Duke University	
	Senior Advisor	Blackstone Group Inc	
Ian E L Davis	Board Member	Cigna Corp	
	Board Member	Gary & Mary West Wireless Heal	
	Board Member	Alignment Healthcare Inc	
	Board Member	Johnson & Johnson	
	Board Member	Arbormetrix Inc	
	Senior Advisor	Apax Partners Llp	
	Chairman	Vickers Pension Trustees Ltd	
Board Member	Thoughtworks Inc		

Ticker:	JNJ US EQUITY	Johnson & Johnson											
Period Type:	Annuals	Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos											
Annuals													
FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY		


Key Financials	Actuals											LTM		Estimates	
	For the Fiscal Period Ending	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	03/07/2022	03/07/2022	03/07/2022	31/12/2022	31/12/2023	31/12/2024		
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD		
Total Revenue	70,074.0	71,890.0	76,450.0	81,581.0	82,059.0	USD03/01/2021	USD03/07/2022	USD03/07/2022	USD03/07/2022	USD31/12/2022	23,646.6	23,646.6			
<i>Growth Over Prior Year</i>	(5.7%)	2.6%	6.3%	6.7%	0.6%	0.6%	13.6%	7.2%	1.3%	1.3%	1.3%	1.3%	01/08/2022		
Gross Profit	48,538.0	50,205.0	51,011.0	54,490.0	54,503.0	54,157.0	63,920.0	64,866.0	--	--	--	--			
<i>Margin %</i>	69.3%	69.8%	66.7%	66.8%	66.4%	--	--	--	--	--	--	--			
EBITDA	21,811.0	24,890.0	24,131.0	26,978.0	27,389.0	27,264.0	31,337.0	29,901.0	8,905.0	8,905.0	8,905.0	8,905.0			
<i>Margin %</i>	31.1%	34.6%	31.6%	33.1%	33.4%	--	--	--	--	--	37.7%	37.7%			
EBIT	18,065.0	21,136.0	18,489.0	20,049.0	20,080.0	19,733.0	23,647.0	22,731.0	7,862.9	7,862.9	7,862.9	7,862.9			
<i>Margin %</i>	25.8%	29.4%	24.2%	24.6%	24.5%	--	--	--	--	--	33.3%	33.3%			
Earnings from Cont. Ops.	15,409.0	16,540.0	1,300.0	15,297.0	15,119.0	14,714.0	20,878.0	18,366.0	--	--	--	--			
<i>Margin %</i>	22.0%	23.0%	1.7%	18.8%	18.4%	--	--	--	--	--	--	--			
Net Income	15,409.0	16,540.0	1,300.0	15,297.0	15,119.0	14,714.0	20,878.0	18,366.0	6,765.0	6,765.0	6,765.0	6,765.0			
<i>Margin %</i>	22.0%	23.0%	1.7%	18.8%	18.4%	--	--	--	--	--	28.6%	28.6%			
Diluted EPS Excl. Extra Items	5.5	5.9	0.5	5.6	5.6	5.5	7.8	6.9	2.6	2.6	2.6	2.6			
<i>Growth Over Prior Year</i>	(3.9%)	8.2%	(92.1%)	1.093.6%	0.4%	(2.1%)	41.7%	3.3%	(1.7%)	(1.7%)	(1.7%)	(1.7%)			

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	173.91
Shares Out.	2,629.18
Market Capitalization (USD)	457,240.68
- Cash & Short Term Investments	32,568.00
+ Total Debt	32,597.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	457,269.68
Book Value of Common Equity	76,357.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	32,597.00
= Total Capital	108,954.00



Valuation Multiples based on Current Capitalization	Actual		Estimates		
	03/07/2022	03/07/2022	03/07/2022	03/07/2022	03/07/2022
TEV/Total Revenue	4.8x	4.9x	19.2x	19.2x	19.2x
TEV/EBITDA	14.5x	15.8x	12.8x	12.8x	12.8x
TEV/EBIT	19.2x	20.8x	14.6x	14.6x	14.6x
P/Diluted EPS Before Extra	21.9x	26.1x			
P/BV	6.1x	6.2x	5.8x	5.8x	5.8x
Price/Tang BV	--	--			

Valuation Multiples for Chart	For the Fiscal Period Ending			
	TTM	FY1	NTM	FY2
PE Ratio	20.5x	17.4x	17.4x	17.4x
TEV / EBITDA	15.8x	12.8x	12.8x	12.8x
Price / CF	19.5x	15.8x	15.8x	15.8x
Price / Book	6.0x	5.8x	5.8x	5.8x
Dividend Yield	2.5x	2.6x	2.6x	2.6x



Ticker:	JNJ US EQUITY
Period Type	Annuals

JNJ US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
Other Revenue	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
Cost Of Goods Sold	20,360.00	21,658.00	22,342.00	22,746.00	21,536.00	21,685.00	25,439.00	27,091.00	27,556.00	28,427.00	29,855.00
Gross Profit	44,670.00	45,566.00	48,970.00	51,585.00	48,538.00	50,205.00	51,011.00	54,490.00	54,503.00	54,157.00	63,920.00
Selling General & Admin Exp.	21,538.00	22,032.00	22,410.00	22,132.00	21,427.00	19,974.00	21,928.00	23,666.00	23,068.00	22,265.00	25,559.00
R & D Exp.	7,548.00	7,665.00	8,183.00	8,494.00	9,046.00	9,095.00	10,594.00	10,775.00	11,355.00	12,159.00	14,714.00
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense., Total	29,086.00	29,697.00	30,593.00	30,626.00	30,473.00	29,069.00	32,522.00	34,441.00	34,423.00	34,424.00	40,273.00
Operating Income	15,584.00	15,869.00	18,377.00	20,959.00	18,065.00	21,136.00	18,489.00	20,049.00	20,080.00	19,733.00	23,647.00
Interest Expense	571.00	532.00	482.00	533.00	552.00	726.00	934.00	1,005.00	318.00	201.00	183.00
Interest Income	91.00	64.00	74.00	67.00	128.00	368.00	385.00	611.00	357.00	111.00	53.00
Net Interest Exp.	480.00	468.00	408.00	466.00	424.00	358.00	549.00	394.00	(39.00)	90.00	130.00
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	1,277.00	574.00	852.00	1,088.00	910.00	863.00	619.00	1,151.00	930.00	3,257.00	1,358.00
EBT Excl. Unusual Items	13,827.00	14,827.00	17,117.00	19,405.00	16,731.00	19,915.00	17,321.00	18,504.00	19,189.00	16,386.00	22,159.00
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	(2,383.00)	(2,583.00)	(563.00)	(1,307.00)	(1,217.00)	(2,154.00)	(111.00)	(617.00)
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	1,466.00	1,052.00	1,646.00	1,225.00	118.00	675.00	955.00	1,722.00	4,015.00	-	-
Other Unusual Items	(2,932.00)	(2,104.00)	(3,292.00)	2,316.00	4,930.00	(224.00)	704.00	(1,010.00)	(3,722.00)	222.00	1,234.00
EBT Incl. Unusual Items	12,361.00	13,775.00	15,471.00	20,563.00	19,196.00	19,803.00	17,673.00	17,999.00	17,328.00	16,497.00	22,776.00
Income Tax Expense	2,689.00	3,261.00	1,640.00	4,240.00	3,787.00	3,263.00	16,373.00	2,702.00	2,209.00	1,783.00	1,898.00
Earnings from Cont. Ops.	9,672.00	10,514.00	13,831.00	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	-	(339.00)	-	-	-	-	-	-	-	-	-
Net Income	9,672.00	10,853.00	13,831.00	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	9,672.00	10,853.00	13,831.00	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00
Abnormal Losses (Gains)	4,992.00	4,439.00	3,643.00	(1,751.00)	(671.00)	1,685.00	3,752.00	4,270.00	6,413.00	4,713.00	2,991.00
Tax Effect on Abnormal Items	(797.00)	(947.00)	(1,633.75)	984.05	241.85	(342.90)	12,507.00	(1,286.70)	(1,885.07)	(1,371.90)	(1,599.50)
NI to Common Excl. Extra Items	13,867.00	14,345.00	15,840.25	15,556.05	14,979.85	17,882.10	17,559.00	18,280.30	19,646.93	18,055.10	22,269.50
Per Share Items											
Basic EPS	3.54	3.94	4.92	5.80	5.56	6.04	0.48	5.70	5.72	5.59	7.93
Basic EPS Excl. Extra Items	3.54	3.94	4.92	5.80	5.56	6.04	0.48	5.70	5.72	5.59	7.93
Weighted Avg. Basic Shares Out.	2,736.00	2,753.30	2,809.20	2,815.20	2,771.80	2,737.30	2,692.00	2,681.50	2,645.10	2,632.80	2,632.10
Diluted EPS	3.49	3.86	4.81	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81
Diluted EPS Excl. Extra Items	3.49	3.86	4.81	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81
Weighted Avg. Diluted Shares Out.	2,775.30	2,812.60	2,877.00	2,863.90	2,812.90	2,788.90	2,745.30	2,728.70	2,684.30	2,670.70	2,674.00
Normalized Basic EPS	5.00	5.10	5.52	5.97	6.20	6.73	7.30	8.18	8.68	8.03	9.80
Normalized Diluted EPS	5.00	5.10	5.51	5.43	5.33	6.41	6.39	6.70	7.32	6.76	8.33
Dividends per Share	2.25	2.40	2.59	2.76	2.95	3.15	3.32	3.54	3.75	3.98	4.19
Payout Ratio %	63.65	60.89	52.61	47.60	53.07	52.13	687.50	62.05	65.61	71.21	52.82
Supplemental Items											
EBITA	16,442.00	17,035.00	19,781.00	22,354.00	19,311.00	22,390.00	21,531.00	24,378.00	24,889.00	24,664.00	28,637.00
EBIT	15,584.00	15,869.00	18,377.00	20,959.00	18,065.00	21,136.00	18,489.00	20,049.00	20,080.00	19,733.00	23,647.00
As Reported Total Revenue*	65,030.00	-	-	-	-	-	-	81,581.00	82,059.00	82,584.00	93,775.00
Effective Tax Rate %	21.75	23.67	10.60	20.62	19.73	16.48	92.64	15.01	12.75	10.81	8.33
Normalized Net Income	13,867.00	14,345.00	15,840.25	15,556.05	14,979.85	17,882.10	17,559.00	18,280.30	19,646.93	18,055.10	22,269.50
Interest Capitalized	84.00	115.00	105.00	115.00	102.00	102.00	94.00	86.00	70.00	63.00	49.00
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	621.00	662.00	728.00	792.00	874.00	878.00	962.00	978.00	977.00	1,005.00	1,135.00
Stock-Based Comp., Total	621.00	662.00	728.00	792.00	874.00	878.00	962.00	978.00	977.00	1,005.00	1,135.00

Ticker:	JNJ US EQUITY
Period Type	Annuals

JNJ US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	24,542.00	14,911.00	20,927.00	14,523.00	13,732.00	18,972.00	17,824.00	18,107.00	17,305.00	13,985.00	14,487.00
Short Term Investments	7,719.00	6,178.00	8,279.00	18,566.00	24,644.00	22,935.00	472.00	1,580.00	1,982.00	11,200.00	17,121.00
Total Cash & ST Investments	32,261.00	21,089.00	29,206.00	33,089.00	38,376.00	41,907.00	18,296.00	19,687.00	19,287.00	25,185.00	31,608.00
Accounts & Notes Receivable	10,581.00	11,309.00	11,713.00	10,985.00	10,734.00	11,699.00	13,490.00	14,098.00	14,481.00	13,576.00	15,283.00
Total Receivables	10,581.00	11,309.00	11,713.00	10,985.00	10,734.00	11,699.00	13,490.00	14,098.00	14,481.00	13,576.00	15,283.00
Inventories	6,285.00	7,495.00	7,878.00	8,184.00	8,053.00	8,144.00	8,765.00	8,599.00	9,020.00	9,344.00	10,387.00
Prepaid Exp.	2,633.00	3,084.00	4,003.00	3,486.00	3,047.00	3,282.00	2,537.00	2,699.00	2,392.00	3,132.00	3,701.00
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2,556.00	3,139.00	3,607.00	-	-	-	-	950.00	94.00	-	-
Total Current Assets	54,316.00	46,116.00	56,407.00	55,744.00	60,210.00	65,032.00	43,088.00	46,033.00	45,274.00	51,237.00	60,979.00
Net Property, Plant & Equipment	14,739.00	16,097.00	16,710.00	16,126.00	15,905.00	15,912.00	17,005.00	17,035.00	18,615.00	18,766.00	18,962.00
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	6,540.00	4,541.00	3,872.00	6,202.00	5,490.00	6,148.00	7,105.00	7,640.00	7,819.00	8,534.00	10,223.00
Other Long-Term Assets	38,049.00	54,593.00	55,694.00	52,286.00	51,806.00	54,116.00	90,105.00	82,246.00	86,020.00	96,357.00	91,854.00
Total Assets	113,644.00	121,347.00	132,683.00	130,358.00	133,411.00	141,208.00	157,303.00	152,954.00	157,728.00	174,894.00	182,018.00
LIABILITIES											
Accrued Exp.	9,574.00	12,691.00	13,787.00	13,314.00	13,325.00	13,714.00	17,467.00	20,079.00	23,952.00	28,965.00	29,293.00
Short-term Borrowings	6,658.00	4,676.00	4,852.00	3,638.00	7,004.00	4,684.00	3,906.00	2,796.00	1,471.00	2,631.00	3,766.00
Accounts Payable	5,725.00	5,831.00	6,266.00	7,633.00	6,668.00	6,918.00	7,310.00	7,537.00	8,544.00	9,505.00	11,055.00
Curr. Income Taxes Payable	854.00	1,064.00	770.00	446.00	750.00	971.00	1,854.00	818.00	2,266.00	1,392.00	1,112.00
Other Current Liabilities	-	-	-	-	-	-	-	-	(269.00)	-	-
Total Current Liabilities	22,811.00	24,262.00	25,675.00	25,031.00	27,747.00	26,287.00	30,537.00	31,230.00	35,964.00	42,493.00	45,226.00
Long-Term Debt	12,969.00	11,489.00	13,328.00	15,122.00	12,857.00	22,442.00	30,675.00	27,684.00	27,210.00	33,735.00	30,985.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	20,784.00	20,770.00	19,627.00	20,453.00	21,657.00	22,061.00	35,931.00	34,288.00	35,083.00	35,388.00	31,784.00
Total Liabilities	56,564.00	56,521.00	58,630.00	60,606.00	62,261.00	70,790.00	97,143.00	93,202.00	98,257.00	111,616.00	107,995.00
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
Total Pref. Equity	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Additional Paid In Capital	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00
Retained Earnings	81,251.00	85,992.00	89,493.00	97,245.00	103,879.00	110,551.00	101,793.00	106,216.00	110,659.00	113,890.00	123,060.00
Treasury Stock	(21,659.00)	(18,476.00)	(15,700.00)	(19,891.00)	(22,684.00)	(28,352.00)	(31,554.00)	(34,362.00)	(38,417.00)	(38,490.00)	(39,099.00)
Comprehensive Inc. and Other	(5,632.00)	(5,810.00)	(2,860.00)	(10,722.00)	(13,165.00)	(14,901.00)	(13,199.00)	(15,222.00)	(15,891.00)	(15,242.00)	(13,058.00)
Total Common Equity	57,080.00	64,826.00	74,053.00	69,752.00	71,150.00	70,418.00	60,160.00	59,752.00	59,471.00	63,278.00	74,023.00
Total Equity	57,080.00	64,826.00	74,053.00	69,752.00	71,150.00	70,418.00	60,160.00	59,752.00	59,471.00	63,278.00	74,023.00
Total Liabilities And Equity	113,644.00	121,347.00	132,683.00	130,358.00	133,411.00	141,208.00	157,303.00	152,954.00	157,728.00	174,894.00	182,018.00
Supplemental Items											
Total Shares Out. on Filing Date	2,724.36	2,778.49	2,820.63	2,783.22	2,755.16	2,706.51	2,682.53	2,662.32	2,632.51	2,632.51	2,628.97
Total Shares Out. on Balance Sheet Date	2,724.36	2,778.49	2,820.63	2,783.22	2,755.16	2,706.51	2,682.53	2,662.32	2,632.51	2,632.51	2,628.97
Book Value/Share	20.95	23.33	26.25	25.06	25.82	26.02	22.43	22.44	22.59	24.04	28.16
Tangible Book Value	22,804.00	13,650.00	23,308.00	20,698.00	23,757.00	20,737.00	(24,974.00)	(18,312.00)	(21,811.00)	(26,517.00)	(7,615.00)
Tangible Book Value/Share	8.37	4.91	8.26	7.44	8.62	7.66	(9.31)	(6.88)	(8.29)	(10.07)	(2.90)
Total Debt	19,627.00	16,165.00	18,180.00	18,760.00	19,861.00	27,126.00	34,581.00	30,480.00	28,681.00	36,366.00	34,751.00
Net Debt	(12,634.00)	(4,924.00)	(11,026.00)	(14,329.00)	(18,515.00)	(14,781.00)	16,285.00	10,793.00	9,394.00	11,181.00	3,143.00
Total Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Inventories Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	1,206.00	1,416.00	1,224.00	1,214.00	936.00	952.00	1,140.00	1,114.00	1,117.00	1,410.00	1,592.00
Work in Progress Inventory	1,637.00	2,262.00	2,612.00	2,461.00	2,241.00	2,185.00	2,317.00	2,109.00	1,832.00	2,040.00	2,287.00
Finished Goods Inventory	3,442.00	3,817.00	4,042.00	4,509.00	4,876.00	5,007.00	5,308.00	5,376.00	6,071.00	5,894.00	6,508.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	361.00	466.00	333.00	275.00	268.00	252.00	291.00	248.00	226.00	293.00	230.00
Full Time Employees	117,900.00	127,600.00	128,100.00	126,500.00	127,100.00	126,400.00	134,000.00	135,100.00	132,200.00	134,500.00	144,300.00

Ticker: JNJ US EQUITY
 Period Type: Annuals

Sort: Ascend
 Consolidated: Yes

Accounting: Mixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples		01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
TEV / LTM Total Revenue	Close	2.6x	2.8x	3.5x	3.7x	3.8x	4.1x	5.1x	4.3x	4.8x	5.2x	4.8x
	Average	2.6x	2.6x	3.5x	3.8x	3.5x	4.2x	4.7x	4.9x	4.5x	4.8x	5.4x
	High	2.8x	2.9x	3.9x	4.1x	3.8x	4.7x	5.2x	5.4x	4.9x	5.2x	5.9x
	Low	2.4x	2.4x	2.8x	3.3x	3.2x	3.5x	4.0x	4.3x	4.2x	3.7x	4.8x
TEV / LTM EBITDA	Close	8.9x	9.6x	11.1x	11.2x	12.1x	11.9x	16.2x	13.0x	14.4x	15.6x	14.5x
	Average	8.4x	9.2x	12.0x	12.1x	10.6x	13.4x	13.5x	15.5x	13.7x	14.4x	16.4x
	High	9.0x	10.0x	13.6x	13.1x	12.2x	15.0x	16.2x	17.2x	14.7x	15.6x	17.7x
	Low	7.5x	8.4x	9.7x	10.4x	9.5x	11.3x	11.6x	13.1x	12.8x	11.0x	14.5x
TEV / LTM EBIT	Close	10.7x	11.9x	13.6x	13.3x	14.6x	14.1x	21.2x	17.4x	19.5x	21.6x	19.2x
	Average	9.9x	11.0x	14.8x	14.8x	12.5x	16.2x	15.9x	20.2x	18.4x	19.6x	22.6x
	High	10.7x	12.0x	16.7x	16.1x	14.7x	18.1x	21.2x	22.4x	19.8x	21.6x	24.5x
	Low	8.9x	10.1x	11.9x	12.7x	11.3x	13.6x	13.7x	17.6x	17.2x	15.0x	19.2x
Price / LTM EPS	Close	13.1x	13.6x	16.8x	19.3x	19.3x	18.0x	21.9x	19.0x	19.9x	23.3x	20.5x
	Average	13.3x	13.4x	16.8x	18.3x	18.4x	21.3x	20.2x	20.8x	20.1x	19.9x	24.5x
	High	14.3x	14.5x	18.7x	19.8x	19.6x	23.5x	22.4x	23.2x	21.8x	23.3x	26.5x
	Low	12.1x	12.4x	13.7x	15.7x	16.7x	18.0x	17.4x	18.7x	18.8x	15.2x	20.5x
Price / Book Value	Close	3.1x	3.0x	3.5x	4.2x	4.0x	4.4x	6.2x	5.7x	6.5x	6.5x	6.1x
	Average	3.1x	3.2x	3.7x	3.8x	4.0x	4.4x	5.0x	5.9x	6.0x	6.5x	6.9x
	High	3.3x	3.5x	4.1x	4.2x	4.2x	4.9x	6.2x	6.6x	6.5x	6.9x	7.5x
	Low	2.8x	2.9x	3.0x	3.3x	3.6x	3.7x	4.3x	5.3x	5.6x	4.9x	6.1x
Price / Tangible Book Value	Close	7.8x	14.1x	11.2x	14.1x	11.9x	15.0x	--	--	--	--	--
	Average	7.1x	8.0x	17.4x	12.2x	13.4x	13.2x	16.9x	--	--	--	--
	High	7.8x	14.1x	19.5x	14.1x	14.3x	15.0x	18.7x	--	--	--	--
	Low	6.4x	7.4x	11.2x	10.5x	11.9x	11.1x	14.6x	--	--	--	--
Price / Cash Flow	Close	12.5x	12.4x	14.9x	15.8x	14.5x	16.8x	17.9x	15.4x	16.5x	17.6x	19.2x
	Average	10.7x	12.8x	15.3x	16.2x	15.0x	16.1x	18.9x	17.0x	16.3x	16.5x	18.5x
	High	12.5x	13.9x	17.1x	17.6x	16.0x	17.8x	20.9x	18.9x	17.7x	17.6x	20.1x
	Low	9.7x	11.8x	12.5x	14.0x	13.7x	13.6x	16.3x	15.3x	15.2x	12.6x	17.1x
TEV / LTM FCF	Close	15.7x	15.4x	18.8x	19.7x	17.7x	20.3x	21.2x	18.4x	19.4x	20.5x	22.8x
	Average	12.5x	16.1x	18.9x	20.5x	18.7x	19.6x	22.8x	20.1x	19.5x	19.4x	21.6x
	High	15.7x	17.4x	21.1x	22.2x	20.0x	21.6x	25.3x	22.4x	21.2x	20.7x	23.4x
	Low	11.3x	14.8x	15.5x	17.6x	17.0x	16.5x	19.7x	18.1x	18.2x	14.8x	20.0x
Dividend Yield	Close	3.4	3.5	2.8	2.6	2.9	2.7	2.4	2.8	2.6	2.5	2.4
	Average	3.3	3.4	2.8	2.6	2.8	2.6	2.4	2.5	2.6	2.6	2.4
	High	3.7	3.6	3.4	3.0	3.0	3.1	2.8	2.8	2.8	3.4	2.6
	Low	3.1	3.1	2.5	2.4	2.6	2.4	2.2	2.2	2.4	2.4	2.2

Ticker:	JNJ US EQUITY
Period Type:	Quarters

JNJ US EQUITY	Ascend
Consolidated	Yes

Accounting	Mixed
------------	-------

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Ratios	-10FQ	-9FQ	-8FQ	-7FQ	-6FQ	-5FQ	-4FQ	-3FQ	-2FQ	-1FQ	0FQ
For the Fiscal Period Ending	29/12/2019	29/03/2020	28/06/2020	27/09/2020	03/01/2021	04/04/2021	04/07/2021	03/10/2021	02/01/2022	03/04/2022	03/07/2022
Profitability											
Return on Assets	9.7%	11.3%	9.7%	10.4%	8.8%	9.2%	10.6%	10.2%	11.7%	11.3%	10.4%
Return on Capital	17.3%	19.5%	16.7%	18.0%	15.9%	16.3%	18.3%	17.5%	20.2%	19.2%	17.4%
Return on Equity	25.4%	28.6%	24.5%	27.7%	24.0%	23.8%	26.8%	26.5%	30.4%	28.2%	25.2%
Margin Analysis											
Gross Margin	65.6%	65.9%	64.1%	66.9%	65.2%	68.4%	67.5%	68.9%	67.9%	67.6%	67.0%
SG&A Margin	29.1%	25.1%	27.2%	25.7%	28.7%	24.3%	26.0%	25.7%	28.8%	25.3%	25.9%
EBITDA Margin	33.4%	34.7%	33.9%	33.5%	32.7%	33.1%	33.9%	33.1%	33.1%	31.7%	31.3%
EBIT Margin	24.5%	26.0%	25.0%	24.7%	23.9%	24.4%	25.5%	24.9%	25.2%	24.0%	23.8%
Earnings from Cont. Ops Margin	20.9%	28.3%	22.1%	27.0%	18.4%	29.8%	26.8%	24.7%	20.1%	24.8%	25.7%
Net Income Margin	19.3%	28.0%	19.8%	16.9%	7.7%	27.8%	26.9%	15.7%	19.1%	22.0%	20.0%
Normalized Net Income Margin	20.4%	26.3%	19.3%	24.6%	17.8%	26.4%	24.0%	25.6%	18.9%	25.8%	24.9%
Free Cash Flow Margin	24.8%	13.2%	15.2%	36.3%	31.2%	15.2%	19.3%	32.3%	17.4%	14.4%	19.6%
Asset Turnover											
Total Asset Turnover	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x
Fixed Asset Turnover	4.6x	4.7x	4.5x	4.5x	4.4x	4.7x	4.9x	5.0x	5.0x	5.1x	5.2x
Accounts Receivable Turnover	5.7x	5.7x	5.5x	5.5x	5.9x	5.6x	6.0x	6.2x	6.5x	6.2x	6.2x
Inventory Turnover	3.1x	3.1x	3.0x	3.0x	3.1x	3.0x	3.0x	3.0x	3.0x	2.9x	2.9x
Short Term Liquidity											
Current Ratio	1.3x	1.3x	1.2x	1.5x	1.2x	1.3x	1.4x	1.3x	1.3x	1.4x	1.4x
Quick Ratio	0.9x	1.0x	0.9x	1.2x	0.9x	1.0x	1.0x	1.0x	1.0x	1.1x	1.1x
Cash from Ops. To Curr Liab	0.5x	0.5x	0.5x	0.8x	0.6x	0.6x	0.7x	0.7x	0.7x	0.7x	0.7x
Ave. Davs Sales Out.	63.4x	63.8x	66.2x	66.1x	63.0x	65.7x	61.4x	59.8x	56.0x	58.6x	59.0x
Ave. Davs Inventor Out.	116.4x	116.7x	123.0x	123.1x	119.8x	122.8x	123.0x	124.8x	120.3x	125.4x	127.6x
Ave. Davs Pavaible Out.	104.6x	93.9x	89.5x	93.9x	116.5x	100.0x	95.3x	97.3x	171.1x	103.1x	104.8x
Ave. Cash Conversion Cvcle	75.1x	86.6x	99.7x	95.4x	66.4x	88.4x	89.1x	87.3x	55.2x	80.8x	81.8x
Long Term Solvency											
Total Debt/Equity	48.2%	45.0%	48.3%	58.6%	57.5%	51.1%	48.1%	48.3%	46.9%	44.4%	42.7%
Total Debt/Capital	32.5%	31.0%	32.6%	36.9%	36.5%	33.8%	32.5%	32.6%	31.9%	30.7%	29.9%
LT Debt/Equity	45.8%	41.4%	39.8%	50.7%	53.3%	46.0%	43.6%	42.9%	41.9%	38.6%	37.1%
LT Debt/Capital	30.9%	28.6%	26.8%	32.0%	33.9%	30.4%	29.4%	28.9%	28.5%	26.7%	26.0%
Total Liabilities/Total Assets	39.5%	38.7%	37.0%	39.5%	39.5%	38.1%	38.6%	35.9%	34.5%	33.8%	31.8%
EBIT / Interest Exp.	51.08x	233.84x	90.02x	129.57x	47.53x	105.52x	156.45x	288.30x	82.92x	581.80x	162.42x
FRITDA / Interest Fxn.	73.39x	303.77x	128.38x	170.89x	69.83x	135.59x	202.43x	378.00x	113.63x	758.70x	208.37x
(EBITDA-CAPEX) / Interest Exp.	58.56x	278.72x	113.67x	154.14x	54.62x	124.84x	182.10x	341.65x	90.05x	698.00x	185.61x
Total Debt/EBITDA	1.05x	0.96x	1.11x	1.39x	1.35x	1.20x	1.11x	1.12x	1.12x	1.10x	1.09x
Net Debt/EBITDA	0.34x	0.33x	0.41x	0.26x	0.41x	0.32x	0.27x	0.10x	0.10x	0.09x	0.00x
Altman Z Score	6.46	6.45	6.4	5.86	5.96	6.25	6.38	6.02	6.12	6.4	6.46
Growth Over Prior Year											
Total Revenue	1.7%	3.3%	(10.8%)	1.7%	8.3%	7.9%	27.1%	10.7%	10.4%	5.0%	3.0%
Gross Profit	1.3%	1.7%	(13.7%)	1.8%	7.7%	12.0%	33.8%	14.0%	14.9%	3.7%	2.4%
EBITDA	4.8%	21.0%	(19.4%)	(2.6%)	(2.6%)	12.5%	40.2%	0.8%	12.2%	(11.2%)	(2.2%)
FRITA	5.2%	23.4%	(21.3%)	(3.5%)	(3.5%)	12.9%	44.1%	0.6%	13.4%	(11.9%)	(2.5%)
EBIT	2.9%	31.7%	(25.1%)	(3.2%)	(4.8%)	13.7%	54.5%	1.1%	20.3%	(12.5%)	(1.4%)
Earnings from Cont. Ops.	31.8%	54.6%	(35.3%)	102.7%	(56.7%)	6.9%	73.1%	3.2%	172.5%	(16.9%)	(23.3%)
Net Income	31.8%	54.6%	(35.3%)	102.7%	(56.7%)	6.9%	73.1%	3.2%	172.5%	(16.9%)	(23.3%)
Normalized Net Income	(4.3%)	13.0%	(40.8%)	8.6%	(5.2%)	8.2%	58.0%	15.2%	17.2%	2.6%	7.1%
Diluted EPS before Extra	33.9%	56.1%	(34.6%)	101.5%	(56.7%)	6.9%	72.8%	3.0%	172.3%	(16.8%)	(23.4%)
Accounts Receivable	2.7%	5.4%	(0.1%)	(1.5%)	(6.2%)	0.4%	1.5%	2.3%	12.6%	4.4%	8.5%
Inventory	4.9%	(2.4%)	1.7%	4.6%	3.6%	12.2%	7.2%	8.2%	11.2%	10.4%	13.2%
Net PP&E	9.3%	(2.7%)	(3.5%)	(0.9%)	0.8%	5.6%	5.9%	3.5%	1.0%	1.8%	(1.5%)
Total Assets	3.1%	3.3%	2.1%	9.8%	10.9%	11.3%	11.4%	5.0%	4.1%	3.4%	0.7%
Tangible Book Value	20.5%	1.5%	(17.2%)	(26.6%)	21.6%	7.4%	(10.0%)	(22.4%)	(71.2%)	(77.8%)	(98.7%)
Common Equity	(0.5%)	4.0%	3.6%	10.8%	6.4%	7.4%	10.5%	9.0%	17.0%	13.5%	9.7%
Cash from Ops.	2.5%	(5.2%)	(42.0%)	11.4%	30.4%	21.3%	53.9%	(1.1%)	(31.3%)	(2.3%)	5.0%
Capital Expenditures	(4.4%)	(4.7%)	(20.9%)	(1.1%)	5.0%	8.3%	22.8%	1.4%	7.0%	(10.3%)	6.2%
Levered Free Cash Flow	4.3%	(5.3%)	(45.4%)	12.7%	36.6%	24.3%	61.3%	(1.3%)	(38.5%)	(0.7%)	4.8%
Unlevered Free Cash Flow	4.9%	(53.6%)	(94.9%)	16.4%	65.4%	223.7%	1.205.3%	(4.7%)	(65.0%)	(20.7%)	2.2%
Dividend per Share	5.6%	12.2%	11.6%	6.3%	4.7%	0.0%	0.0%	5.0%	6.5%	5.0%	6.6%

CAGR Over Two Years

Total Revenue	1.4%	1.7%	(6.2%)	1.8%	5.0%	5.6%	6.5%	6.1%	9.3%	6.4%	14.5%
Gross Profit	2.6%	0.9%	(8.0%)	1.3%	4.5%	6.7%	7.4%	7.7%	11.3%	7.8%	17.0%
EBITDA	15.1%	0.8%	(10.7%)	9.1%	1.0%	16.7%	6.3%	(0.9%)	4.5%	(0.0%)	17.1%
EBITA	19.2%	0.9%	(11.5%)	10.2%	0.7%	18.0%	6.5%	(1.4%)	4.6%	(0.3%)	18.5%
FRIT	23.6%	1.0%	(14.3%)	11.5%	(1.0%)	22.4%	7.6%	(1.0%)	7.0%	(0.2%)	23.4%
Earnings from Cont. Ops.	--	15.2%	(4.2%)	(5.0%)	(24.4%)	28.6%	5.8%	44.6%	8.7%	(5.7%)	15.2%
Net Income	--	15.2%	(4.2%)	(5.0%)	(24.4%)	28.6%	5.8%	44.6%	8.7%	(5.7%)	15.2%
Normalized Net Income	4.7%	8.3%	(13.7%)	5.9%	(4.8%)	10.6%	(3.3%)	11.8%	5.4%	5.3%	30.1%
Diluted EPS before Extra	--	16.5%	(3.2%)	(3.9%)	(23.8%)	29.2%	6.3%	44.1%	8.6%	(5.7%)	15.0%
Accounts Receivable	3.6%	2.5%	1.9%	1.9%	(1.9%)	2.9%	0.7%	0.4%	2.7%	2.4%	5.0%
Inventory	1.4%	(0.8%)	3.4%	5.2%	4.2%	4.7%	4.4%	6.4%	7.3%	11.3%	10.2%
Net PP&F	4.6%	1.1%	2.9%	3.6%	5.0%	1.4%	1.1%	1.3%	0.9%	3.7%	2.1%
Total Assets	0.1%	(0.5%)	1.0%	4.7%	6.9%	7.2%	6.7%	7.4%	7.4%	7.3%	5.9%
Tangible Book Value	(5.7%)	(0.9%)	3.3%	8.0%	21.0%	4.4%	(13.7%)	(24.5%)	(40.9%)	(51.2%)	(89.1%)
Common Equity	(0.6%)	(1.6%)	0.1%	(0.1%)	2.9%	5.7%	7.0%	9.9%	11.6%	10.4%	10.1%
Cash from Ops.	2.4%	(3.5%)	(24.6%)	15.6%	15.6%	7.2%	(5.5%)	4.9%	(5.3%)	8.9%	27.2%
Capital Expenditures	0.8%	(2.5%)	(13.0%)	(5.1%)	0.2%	1.6%	(1.4%)	0.1%	6.0%	(1.5%)	14.2%
Levered Free Cash Flow	2.8%	(3.7%)	(26.8%)	18.4%	19.4%	8.5%	(6.2%)	5.5%	(8.3%)	11.1%	30.0%
Unlevered Free Cash Flow	0.6%	(42.7%)	(78.3%)	28.1%	31.7%	22.6%	(18.7%)	5.3%	(23.9%)	60.2%	265.2%
Dividend per Share	6.3%	9.7%	8.5%	5.9%	5.1%	5.9%	5.6%	5.6%	5.6%	2.4%	3.2%

CAGR Over Three Years

Total Revenue	4.6%	5.2%	(0.9%)	2.4%	3.6%	3.7%	3.8%	4.7%	6.7%	5.4%	5.3%
Gross Profit	2.7%	3.3%	(3.3%)	3.5%	4.3%	4.4%	4.2%	5.4%	7.8%	5.7%	5.7%
FRITDA	3.2%	5.7%	(4.1%)	5.4%	8.9%	4.6%	3.8%	6.3%	4.6%	6.5%	3.4%
EBITDA	3.9%	6.0%	(4.2%)	5.9%	11.1%	4.7%	4.1%	6.9%	4.8%	7.1%	3.4%
EBIT	(2.1%)	1.9%	(9.2%)	6.5%	13.3%	5.1%	4.3%	8.0%	5.7%	9.4%	4.5%
Earnings from Cont. Ops.	1.7%	9.4%	(1.8%)	(1.9%)	(154.5%)	12.4%	16.7%	(2.3%)	15.9%	11.2%	(5.0%)
Net Income	1.7%	9.4%	(1.8%)	(1.9%)	(154.5%)	12.4%	16.7%	(2.3%)	15.9%	11.2%	(5.0%)
Normalized Net Income	0.6%	4.3%	(8.8%)	6.6%	1.3%	8.3%	5.5%	8.9%	2.1%	7.8%	0.1%
Diluted EPS before Extra	2.8%	10.5%	(1.0%)	(1.0%)	(154.6%)	13.2%	17.5%	(1.6%)	16.5%	11.6%	(4.7%)
Accounts Receivable	7.4%	6.5%	3.3%	3.5%	0.2%	1.8%	1.8%	2.0%	2.7%	3.4%	3.3%
Inventory	3.5%	(0.0%)	(1.0%)	0.3%	2.2%	3.4%	4.7%	6.2%	6.5%	6.5%	7.3%
Net PP&E	5.4%	2.4%	2.3%	2.4%	3.3%	2.5%	3.9%	3.6%	3.6%	1.5%	0.2%
Total Assets	3.8%	2.3%	1.2%	3.1%	3.6%	3.3%	4.3%	4.8%	6.0%	5.9%	4.6%
Tangible Book Value	(202.6%)	(207.6%)	9.5%	13.0%	2.7%	1.8%	(1.4%)	(3.2%)	(25.0%)	(37.7%)	(78.6%)
Common Equity	(5.5%)	(4.5%)	(4.3%)	(4.5%)	1.7%	1.3%	3.4%	2.8%	7.4%	8.2%	7.9%
Cash from Ops.	(1.3%)	4.9%	(15.7%)	10.2%	11.0%	4.2%	(4.4%)	9.7%	(2.8%)	3.9%	(2.1%)
Capital Expenditures	4.9%	3.7%	(1.3%)	(2.3%)	2.2%	1.0%	(2.4%)	(3.0%)	2.4%	(2.6%)	1.0%
Levered Free Cash Flow	(2.6%)	5.1%	(18.1%)	11.8%	13.0%	4.8%	(4.7%)	11.4%	(4.3%)	5.3%	(2.6%)
Unlevered Free Cash Flow	(8.0%)	7.8%	(64.1%)	15.7%	18.7%	2.0%	(15.0%)	16.1%	(15.3%)	6.0%	(12.3%)
Dividend per Share	4.2%	8.1%	8.1%	6.3%	5.8%	6.3%	5.6%	5.6%	5.6%	5.6%	6.0%

CAGR Over Five Years

Total Revenue	2.6%	3.6%	0.6%	4.3%	4.8%	5.0%	4.8%	5.5%	6.5%	5.7%	5.0%
Gross Profit	1.9%	2.4%	(1.1%)	3.5%	3.8%	4.7%	3.6%	5.5%	6.0%	5.1%	4.4%
EBITDA	5.5%	4.0%	(0.1%)	6.2%	7.7%	6.1%	4.2%	3.8%	3.7%	3.3%	3.8%
EBITA	6.0%	4.2%	(0.2%)	5.5%	9.1%	6.5%	4.4%	4.0%	4.1%	3.4%	4.3%
EBIT	2.8%	1.8%	(3.8%)	4.2%	5.5%	4.0%	2.0%	1.4%	1.5%	1.0%	2.7%
Earnings from Cont. Ops.	9.7%	6.1%	(4.3%)	1.1%	(11.6%)	6.8%	9.5%	(3.0%)	4.4%	3.1%	4.7%
Net Income	9.7%	6.1%	(4.3%)	1.1%	(11.6%)	6.8%	9.5%	(3.0%)	4.4%	3.1%	4.7%
Normalized Net Income	3.2%	5.5%	(2.1%)	6.5%	(0.2%)	4.8%	3.9%	6.6%	2.5%	4.7%	5.1%
Diluted EPS before Extra	11.0%	7.2%	(3.3%)	2.1%	(10.8%)	7.8%	10.4%	(2.2%)	5.1%	3.7%	5.2%
Accounts Receivable	5.7%	5.2%	4.1%	5.1%	4.8%	5.5%	4.3%	4.8%	5.5%	4.9%	4.0%
Inventory	2.0%	1.9%	2.6%	3.2%	3.0%	4.0%	3.5%	4.1%	5.0%	4.4%	3.4%
Net PP&E	2.9%	2.5%	2.5%	2.8%	3.4%	2.8%	3.1%	2.8%	3.6%	2.9%	2.2%
Total Assets	3.9%	3.8%	3.7%	5.1%	5.6%	4.8%	4.8%	5.0%	5.2%	4.2%	3.1%
Tangible Book Value	(202.2%)	(201.1%)	(196.9%)	(193.9%)	(203.2%)	(197.4%)	(193.0%)	(190.8%)	(182.3%)	(178.4%)	(56.5%)
Common Equity	(3.1%)	(2.0%)	(2.4%)	(2.1%)	(2.3%)	(2.0%)	(0.8%)	(0.7%)	1.0%	1.2%	1.2%
Cash from Ops.	6.8%	3.2%	(4.9%)	3.2%	10.4%	13.2%	3.1%	9.1%	(2.9%)	6.4%	(0.7%)
Capital Expenditures	(3.4%)	2.9%	(2.9%)	(1.4%)	(0.6%)	1.2%	1.4%	0.3%	5.3%	1.6%	4.6%
Levered Free Cash Flow	10.6%	3.3%	(5.3%)	3.7%	13.5%	17.0%	3.4%	10.3%	(4.9%)	7.5%	(1.5%)
Unlevered Free Cash Flow	18.0%	(9.9%)	(39.3%)	3.0%	21.5%	(207.3%)	1.2%	14.3%	(14.8%)	26.3%	(9.1%)
Dividend per Share	6.3%	7.6%	7.2%	6.1%	7.3%	6.1%	5.8%	5.8%	4.8%	5.8%	6.1%

Ticker: JNJ US EQUITY JNJ US EQUITY Ascend Currency Reporting Change USD
 Period Type: Annuals Consolidated Yes Accounting Mixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
REVENUE											
Revenue by Product											
For the Fiscal Period Ending	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
Pharmaceutical	25,779.00	27,426.00	28,490.00	32,313.00	31,430.00	33,464.00	38,256.00	40,734.00	42,201.00	45,572.00	52,081.00
Medical Devices	24,368.00	25,351.00	28,125.00	27,522.00	25,137.00	25,119.00	26,592.00	26,994.00	25,961.00	22,959.00	27,059.00
Consumer	14,883.00	14,447.00	14,697.00	14,496.00	13,507.00	13,307.00	13,602.00	13,853.00	13,897.00	14,053.00	14,635.00
Corporate	-	-	-	-	-	-	-	-	-	-	-
Spine	-	-	-	-	-	-	-	-	-	-	-
Trauma	-	-	-	-	-	-	-	-	-	-	-
Hips	-	-	-	-	-	-	-	-	-	-	-
Knees	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography											
For the Fiscal Period Ending	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
United States	28,908.00	29,830.00	31,910.00	34,782.00	35,687.00	37,811.00	39,863.00	41,884.00	42,097.00	43,133.00	47,156.00
Europe	17,129.00	16,945.00	18,599.00	18,947.00	15,995.00	15,770.00	17,126.00	18,753.00	18,466.00	18,980.00	23,594.00
Asia-Pacific, Africa	12,575.00	13,242.00	13,382.00	13,442.00	12,347.00	12,575.00	13,420.00	14,831.00	15,555.00	15,136.00	17,275.00
Western Hemisphere excluding U.S.	6,418.00	7,207.00	7,421.00	7,160.00	6,045.00	5,734.00	6,041.00	6,113.00	5,941.00	5,335.00	5,750.00
Reconciliation	-	-	-	-	-	-	-	-	-	-	-
International	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Ticker: JNJ US EQUITY	Sort Ascend	Currency Reporting Change USD
Period Type: Annuals	Consolidated: Yes	Accounting: Mixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	638.00	722.00	906.00	882.00	1,037.00	949.00	1,080.00	1,283.00	1,163.00	1,380.00	1,421.00
Interest Cost	853.00	878.00	908.00	1,018.00	988.00	927.00	927.00	996.00	1,096.00	955.00	770.00
Expected Return on Plan Assets	(1,108.00)	(1,236.00)	(1,447.00)	(1,607.00)	(1,809.00)	(1,962.00)	(2,041.00)	(2,212.00)	(2,322.00)	(2,461.00)	(2,645.00)
Pension Expense (Income)	781.00	865.00	1,055.00	743.00	971.00	422.00	594.00	923.00	593.00	790.00	623.00
Other Postretirement Cost											
Service Cost	149.00	175.00	196.00	211.00	257.00	224.00	247.00	269.00	274.00	287.00	309.00
Interest Cost	188.00	165.00	151.00	197.00	186.00	158.00	159.00	148.00	185.00	133.00	81.00
Expected Return on Plan Assets	(1.00)	(4.00)	(6.00)	(7.00)	(7.00)	(6.00)	(6.00)	(7.00)	(6.00)	(7.00)	(7.00)
Other Postretirement Benefits Expense (I)	378.00	409.00	452.00	503.00	604.00	477.00	508.00	502.00	551.00	524.00	503.00
Pension Funded Status											
Fair Value of Plan Assets	13,736.00	17,536.00	20,901.00	22,575.00	22,254.00	23,633.00	28,404.00	26,818.00	32,201.00	38,195.00	41,930.00
Actual Return (Loss) on Plan Assets	(102.00)	1,926.00	3,573.00	2,078.00	298.00	2,286.00	4,274.00	(1,269.00)	6,185.00	5,524.00	4,439.00
Employer Contribution	1,135.00	1,838.00	565.00	1,176.00	752.00	838.00	664.00	1,140.00	908.00	870.00	969.00
Benefits Paid	(659.00)	(697.00)	(751.00)	(813.00)	(773.00)	(1,210.00)	(1,050.00)	(1,018.00)	(1,555.00)	(1,111.00)	(1,157.00)
Projected Benefit Obligation	17,424.00	21,829.00	21,488.00	26,889.00	25,855.00	28,116.00	33,221.00	31,670.00	37,188.00	43,300.00	41,582.00
Over(Under) Funded Pension	(3,688.00)	(4,293.00)	(587.00)	(4,314.00)	(3,601.00)	(4,483.00)	(4,817.00)	(4,852.00)	(4,987.00)	(5,105.00)	348.00
Accumulated Benefit Obligation	15,452.00	19,267.00	19,203.00	23,816.00	23,262.00	25,319.00	29,793.00	28,533.00	33,416.00	40,356.00	39,049.00
Pension Funding Ratio	78.83	80.33	97.27	83.96	86.07	84.06	85.50	84.68	86.59	88.21	100.84
Other Postretirement Funded Status											
Fair Value of Plan Assets	8.00	122.00	87.00	79.00	74.00	75.00	281.00	180.00	115.00	90.00	102.00
Actual Return (Loss) on Plan Assets	(1.00)	3.00	15.00	8.00	1.00	7.00	12.00	-	19.00	14.00	17.00
Employer Contribution	315.00	543.00	323.00	477.00	414.00	372.00	545.00	282.00	347.00	357.00	343.00
Benefits Paid	(320.00)	(432.00)	(373.00)	(493.00)	(420.00)	(378.00)	(351.00)	(383.00)	(431.00)	(396.00)	(348.00)
Projected Benefit Obligation	3,790.00	4,159.00	4,407.00	5,081.00	4,669.00	4,605.00	4,582.00	4,480.00	5,076.00	5,028.00	4,878.00
Over(Under) Funded Post Ret Benefits	(3,782.00)	(4,037.00)	(4,320.00)	(5,002.00)	(4,595.00)	(4,530.00)	(4,301.00)	(4,300.00)	(4,961.00)	(4,938.00)	(4,776.00)
Other Post-Retirement Funding Ratio	0.21	2.93	1.97	1.55	1.58	1.63	6.13	4.02	2.27	1.79	2.09
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	8.44	8.45	8.46	8.46	8.53	8.55	8.43	8.46	8.31	8.12	7.71
Discount Rate used on Plan Liabilities	5.08	4.25	4.78	3.78	4.11	3.78	3.30	3.76	2.91	2.14	2.49
Rate of Compensation Increase	4.15	4.08	4.08	4.08	4.05	4.02	4.01	3.98	3.99	4.00	4.01
Other Postretirement Benefits											
Expected Return on Plan Assets	9.00	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	5.43	4.55	5.25	5.25	4.31	4.77	4.63	3.85	3.39	2.23	2.68
Health Care Cost Trend Projected(next y)	7.50	6.50	6.50	6.00	6.60	6.32	6.33	6.12	5.87	5.68	5.33
Pension Plan Asset Allocation											
Fair Value of Plan Assets	13,736.00	17,536.00	20,901.00	22,575.00	22,254.00	23,633.00	28,404.00	26,818.00	32,201.00	38,195.00	41,930.00
Asset Category - Equities %	48.78	46.24	50.49	77.00	79.00	75.00	76.00	71.00	74.00	66.00	65.00
Asset Category - Debt %	8.12	9.39	5.82	23.00	21.00	25.00	24.00	29.00	26.00	34.00	35.00
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Other %	43.10	44.37	43.69	-	-	-	-	-	-	-	-
Expected Pension Payments											
Year 1	354.00	316.00	778.00	793.00	839.00	897.00	970.00	1,062.00	1,126.00	1,257.00	1,317.00
Year 2	277.00	221.00	794.00	813.00	872.00	908.00	1,007.00	1,104.00	1,172.00	1,292.00	1,386.00
Year 3	216.00	220.00	840.00	868.00	911.00	958.00	1,057.00	1,182.00	1,234.00	1,388.00	1,421.00
Year 4	218.00	220.00	890.00	907.00	967.00	1,010.00	1,131.00	1,257.00	1,323.00	1,424.00	1,496.00
Year 5	218.00	220.00	933.00	963.00	1,031.00	1,081.00	1,190.00	1,332.00	1,359.00	1,494.00	1,572.00
Beyond Year 5	1,112.00	1,121.00	6,071.00	5,858.00	6,098.00	6,416.00	7,062.00	7,679.00	7,945.00	8,795.00	9,279.00
Expected Postretirement Benefits											
Year 1	--	--	313.00	316.00	331.00	325.00	322.00	375.00	437.00	427.00	447.00
Year 2	--	--	309.00	309.00	322.00	315.00	312.00	397.00	450.00	440.00	459.00
Year 3	--	--	305.00	306.00	315.00	311.00	306.00	411.00	466.00	453.00	472.00
Year 4	--	--	302.00	303.00	312.00	307.00	301.00	428.00	479.00	465.00	485.00
Year 5	--	--	299.00	300.00	310.00	304.00	297.00	413.00	494.00	417.00	434.00
Beyond Year 5	--	--	1,469.00	1,475.00	1,499.00	1,465.00	1,395.00	2,273.00	2,356.00	2,273.00	2,379.00

Ticker: JNJ US EQUITY Sort: Ascend Currency: Reporting Change: USD
 Period Type: Annuals Consolidated: Yes Accounting: Mixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Supplemental											
For the Fiscal Period Ending	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Options Activity											
Options Granted During Period	9.53	8.66	29.01	24.36	20.48	22.49	19.29	17.12	19.75	20.72	18.53
Options Outstanding End Of Period	179.46	134.35	119.56	115.71	116.52	113.46	111.31	109.65	111.64	114.25	117.36
Options Exercisable End of Period	138.13	104.86	75.21	57.85	48.35	50.41	50.41	54.86	60.76	61.29	62.74
Price											
Weighted Average Fair Value per Option	7.47	6.39	4.88	8.42	10.68	10.01	13.38	17.98	-	-	-
Avg Exercise Price (Options Outstanding)	60.10	61.58	64.70	70.37	76.41	83.16	90.48	98.29	105.63	116.22	125.36
Avg Exercise Price (Options Exercisable)	59.94	61.15	62.01	61.94	62.26	65.77	73.61	82.03	-	-	104.42
Stock Option Valuation Model	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Assumptions											
Stock Opt Valuation - Risk Free Rate (%)	2.41	1.06	1.01	1.87	1.77	1.51	2.25	2.77	2.56	1.47	0.83
Stock Opt Valuation - Expected Life (Yrs)	6.00	6.00	6.00	6.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00
Stock Opt Valuation - Expected Volatil (%)	18.20	18.38	14.04	14.60	15.48	15.76	15.30	15.77	16.27	15.33	18.59
Stock Opt Valuation - Dividend Yield (%)	3.60	3.60	3.40	3.10	2.90	3.10	2.90	2.70	2.80	2.60	2.50
Stock Expense											
Expense For Stock-Based Compensation	621.00	662.00	728.00	792.00	874.00	878.00	962.00	978.00	977.00	1,005.00	1,135.00
Stock Option Expense (After Tax)	-	-	-	-	-	-	-	-	-	-	-